Cellectar Biosciences is expected to report a Q3 2026 loss of $0.46 per share on nil revenue, with its $1.22 share price trading significantly below the $11.50 consensus price target. The central narrative for investors is the updated timeline for the New Drug Application (NDA) for iopofosine I-131 in Waldenström’s macroglobulinemia, which is currently targeted for early 2027.
This follows promising 12-month follow-up data from the CLOVER-WaM pivotal trial showing durable clinical responses. Analysts will also closely monitor management’s commentary on the company’s cash runway, as it funds the initiation of its confirmatory Phase 3 study while preparing for a potential commercial launch.